Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck(German Center for Lung Research), Michael Schenker(Oncolab (Romania)), Ki Hyeong Lee(Chungbuk National University Hospital), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Makoto Nishio(The Cancer Institute Hospital), Krzysztof Leśniewski-Kmak(Gdańsk Medical University), Randeep Sangha(University of Alberta), Samreen Ahmed(University Hospitals of Leicester NHS Trust), Judith Raimbourg(Institut de Cancérologie de l'Ouest), Kynan Feeney(Edith Cowan University), R. Corre(Centre Hospitalier Universitaire de Rennes), Fábio Franke(Hospital de Base), Eduardo Richardet(Universidad Católica de Córdoba), John R. Penrod(Bristol-Myers Squibb (United States)), Yong Yuan(Bristol-Myers Squibb (Germany)), Faith E. Nathan(Bristol-Myers Squibb (United States)), Prabhu Bhagavatheeswaran(Bristol-Myers Squibb (United States)), Michael DeRosa(Adelphi Laboratory Center), Fiona Taylor(Adelphi Laboratory Center), Rachael Lawrance(Adelphi Group (United Kingdom)), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center)
Cited by 216Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis